



















Arch Endocrinol Metab. 2018;62/2 
1 Serviço de Endocrinologia, 
Hospital das Clínicas, Universidade 
Federal de Pernambuco 
(UFPE), Recife, PE, Brasil
2 Unidade de Neuroendócrino, 
Escola Paulista de Medicina, 
Universidade Federal de São Paulo 
(Unifesp/EPM), São Paulo, SP, Brasil
3 Centro de Endocrinologia e 
Diabetes de Joinville (Endoville), 
Joinville, SC, Brasil
4 Serviço de Endocrinologia 
do Hospital Universitário de 
Brasília, Universidade de Brasília 
(UnB), Brasília, DF, Brasil
5 Serviço de Endocrinologia e 
Metabologia, Hospital de Clínicas, 
Universidade Federal do Paraná 
(SEMPR), Curitiba, PR, Brasil
6 Divisão de Neurocirurgia Funcional, 
Instituto de Psiquiatria do Hospital 
das Clínicas, Faculdade de Medicina 
da Universidade de São Paulo (IPq-
HC-FMUSP), São Paulo, SP, Brasil
7 Serviço de Endocrinologia, 
Hospital de Clínicas de Porto Alegre, 
PPG Endocrinologia, Faculdade de 
Medicina, Universidade Federal 
do Rio Grande do Sul (UFRGS), 
Porto Alegre, RS, Brasil
8 Serviço de Endocrinologia, 
Hospital das Clínicas, Faculdade de 
Medicina da Universidade de São 
Paulo (FMUSP), São Paulo, SP, Brasil
9 Serviço de Endocrinologia, Hospital 
Universitário Presidente Dutra, 
Universidade Federal do Maranhão 
(UFMA), São Luís, MA, Brasil
10 Serviço de Endocrinologia, 
Hospital Universitário Clementino 
Fraga Filho, Universidade Federal 
do Rio de Janeiro (HUCFF-UFRJ), 
Rio de Janeiro, RJ, Brasil
11 Unidade de Neuroendocrinologia, 
Instituto Estadual do Cérebro Paulo 
Niemeyer, Rio de Janeiro, RJ, Brasil 
12 Departamento de Clínica 
Médica, Faculdade de Ciências 
Médicas, Universidade Estadual 
de Campinas (FCM/Unicamp), 
Campinas, SP, Brasil
13 Serviço de Endocrinologia, 
Hospital Universitário Walter 
Cantídio, Universidade Federal do 
Ceará (UFCE), Fortaleza, CE, Brasil
14 Serviço de Endocrinologia 
e Metabologia, Santa Casa 
de Belo Horizonte, Belo 
Horizonte, MG, Brasil
15 Serviço de Endocrinologia, 
Hospital das Clínicas, Universidade 
Federal de Minas Gerais (UFMG), 




Departamento de Medicina Clínica
Av. Prof. Moraes Rego, 1235,
Cidade Universitária 





Controversial issues in the 
management of hyperprolactinemia 
and prolactinomas – An overview  
by the Neuroendocrinology 
Department of the Brazilian  
Society of Endocrinology 
and Metabolism
Lucio Vilar1, Julio Abucham2, José Luciano Albuquerque1,  
Luiz Antônio Araujo3, Monalisa F. Azevedo4, Cesar Luiz Boguszewski5,  
Luiz Augusto Casulari4, Malebranche B. C. Cunha Neto6,  
Mauro A. Czepielewski7, Felipe H. G. Duarte8, Manuel dos S. Faria9,  
Monica R. Gadelha10,11, Heraldo M. Garmes12, Andrea Glezer8,  
Maria Helane Gurgel13, Raquel S. Jallad8, Manoel Martins13,  
Paulo A. C. Miranda14, Renan M. Montenegro13, Nina R. C. Musolino6, 
Luciana A. Naves4, Antônio Ribeiro-Oliveira Júnior15, Cíntia M. S. Silva10,  
Camila Viecceli7, Marcello D. Bronstein8
ABSTRACT
Prolactinomas are the most common pituitary adenomas (approximately 40% of cases), and they 
represent an important cause of hypogonadism and infertility in both sexes. The magnitude of 
prolactin (PRL) elevation can be useful in determining the etiology of hyperprolactinemia. Indeed, 
PRL levels > 250 ng/mL are highly suggestive of the presence of a prolactinoma. In contrast, most 
patients with stalk dysfunction, drug-induced hyperprolactinemia or systemic diseases present 
with PRL levels < 100 ng/mL. However, exceptions to these rules are not rare. On the other hand, 
among patients with macroprolactinomas (MACs), artificially low PRL levels may result from the 
so-called “hook effect”. Patients harboring cystic MACs may also present with a mild PRL elevation. 
The screening for macroprolactin is mostly indicated for asymptomatic patients and those with 
apparent idiopathic hyperprolactinemia. Dopamine agonists (DAs) are the treatment of choice 
for prolactinomas, particularly cabergoline, which is more effective and better tolerated than 
bromocriptine. After 2 years of successful treatment, DA withdrawal should be considered in all 
cases of microprolactinomas and in selected cases of MACs. In this publication, the goal of the 
Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism (SBEM) 
is to provide a review of the diagnosis and treatment of hyperprolactinemia and prolactinomas, 
emphasizing controversial issues regarding these topics. This review is based on data published in 
the literature and the authors’ experience. Arch Endocrinol Metab. 2018;62(2):236-63
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INTRODUCTION 
Hyperprolactinemia has multiple etiologies (Table 1) and is the most common endocrine disorder of the 
hypothalamic-pituitary axis (1-3). A prolactinoma is the 
most common cause of chronic hyperprolactinemia once 
pregnancy, primary hypothyroidism, and drugs that raise 
serum prolactin (PRL) levels have been ruled out (4-6).
Prolactinomas are the most common hormone-
secreting pituitary tumors,accounting for approximately 
40% of all pituitary tumors (2,6) In adults, prolactinomas 
have an estimated prevalence of 60-100 per million 
population (7,8), and in a population from three 
different districts of Belgium, prolactinomas have been 
reported to represent 73.3% of all pituitary adenomas, 
with a higher prevalence in women (78.2%) (9). Between 
the age of 20 and 50 years, the ratio between women 
and men is estimated to be 10:1, whereas after the fifth 
decade of life, both genders are equally affected (10,11). 
Although prolactinomas are rare at the pediatric and 
adolescent ages, they account for approximately half of 
all pituitary adenomas in that population (12). PRL-
secreting carcinomas are extremely rare (13).
effects of hyperprolactinemia on testes and ovaries. 
Hypogonadism can cause menstrual irregularity 
and amenorrhea in women, sexual dysfunction, 
infertility, and loss of bone mineral mass in both 
genders (15,16). Hyperprolactinemia can also reduce 
the libido independently of testosterone levels (17). 
In patients harboring macroprolactinomas, tumor 
mass effect symptoms, such as headache, visual 
changes, and, more rarely, cerebrospinal fluid (CSF) 
rhinorrhea, hydrocephalus and seizures, can also occur 
(1-3). Hypopituitarism beyond hypogonadism can 
occur if there is compression of the pituitary stalk or 
destruction of normal pituitary tissue (3,6,7). It is 
worth commenting that some women present with 
non-puerperal galactorrhea in the presence of regular 
menstrual cycles and normal PRL levels (18,19). 
This so-called “idiopathic galactorrhea” is estimated 
to be present in up to 40-50% of all women with 
non-puerperal galactorrhea (19,20). In contrast, the 
finding of galactorrhea in men is highly suggestive of a 
prolactinoma (2,18).
In this publication, the goal of the Neuroendocrino-
logy Department of the Brazilian Society of 
Endocrinology and Metabolism (SBEM) is to 
provide a review on the diagnosis and treatment of 
hyperprolactinemia and prolactinomas, emphasizing 
controversial issues regarding these topics. 
PROLACTIN SERUM ISOFORMS
The PRL size is heterogeneous in terms of circulating 
molecular forms. The predominant form in healthy 
subjects and in patients with prolactinomas is monomeric 
PRL (molecular weight of 23 kDa), while dimeric or big 
PRL (45-60 kDa) and big-big PRL or macroprolactin 
(150-170 kDa) correspond to less than 20% of the 
total PRL (20,21). When the serum of a patient with 
hyperprolactinemia contains mostly macroprolactin, 
the condition is termed macroprolactinemia (22,23). 
In up to 90% of cases, macroprolactin is composed of a 
complex formed by an IgG and monomeric PRL (2,24-29).
DIAGNOSTIC EVALUATION
For the correct identification of the etiology of 
hyperprolactinemia, some parameters must be taken 
into account: medical history, physical examination, 
clinical features, laboratory findings (especially 
PRL serum levels), and imaging studies of the 
Table 1. Causes of hyperprolactinemia
Physiologic
• Pregnancy; lactation; stress; sleep; coitus; exercise
Pathologic
• Systemic diseases – Primary hypothyroidism; adrenal insufficiency; renal 
insufficiency; cirrhosis; pseudocyesis; epileptic seizures
• Hypothalamic diseases – tumors (craniopharyngiomas, dysgerminomas, 
meningiomas, etc.); infiltrative disorders (histiocytosis, sarcoidosis, etc.), 
metastasis; cranial radiation; Rathke’s cleft cysts, etc.
• Pituitary diseases – Prolactinomas; acromegaly; thyrotropinomas; Cushing’s 
disease; infiltrative disorders; metastasis; lymphocytic hypophysitis; empty 
sella syndrome, etc.
• Stalk disorders – Hastitis; seccion; traumatic brain injury
• Neurogenic – Chest wall lesions (burns; breast surgery; thoracotomy; nipple 
rings; herpes zoster, etc.); spinal cord injury (cervical ependymoma; tabes 
dorsalis; extrinsic tumors, etc.), breast stimulation, etc.
• Idiopathic
• Ectopic prolactin production – Renal cell carcinoma; ovarian teratomas; 




Adapted from Ref. 1.
The most characteristic signs and symptoms found 
in patients with hyperprolactinemia are those related 
to hypogonadotropic hypogonadism and galactorrhea 
(1,3,7). Increased PRL levels decrease gonadotropin 
pulsatile secretion through inhibition of hypothalamic 
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pituitary and sella turcica (1,3,5). Furthermore, the 
screening for macroprolactinemia should often be 
considered, particularly in cases of asymptomatic 
hyperprolactinemia (3-5).
In addition to PRL determination, TSH, free 
T4, and creatinine levels should be obtained to rule 
out secondary causes of hyperprolactinemia (1,3,6). 
Moreover, acromegaly must be investigated by 
measuring IGF-1 in all patients with a macroadenoma, 
even when there are no manifestations of this disease 
(30). Finally, β-hCG measurement is mandatory in any 
woman of childbearing age with amenorrhea (1,3).
1. CONTROVERSIAL ISSUES REGARDING DIAGNOSIS 
1.1. Environmental influences on PRL secretion 
Prolactin is secreted in a pulsatile manner, and serum 
levels can vary greatly throughout the day, with higher 
levels during sleep, a morning peak and a gradual 
decline after awakening, but without a typical circadian 
rhythm. Under normal conditions, ∼50% of the total 
daily production of PRL occurs during the sleep period. 
Thus, samples should be collected up to 3 hours after 
awakening, preferably while the patient is fasted (1,4). 
Stress from any source, whether psychological, 
induced by exercise or due to other acute illness, 
leads to the physiological elevation of PRL levels 
(2,3,5). However, supine rest is not necessary prior 
to sampling, contrary to what was believed in the 
past (31). Venipuncture stress may cause an elevation 
in the PRL level, but it is usually mild (< 40-60 ng/
mL) (32). The same is true for breast stimulation 
(1,2,33). Moreover, as PRL is secreted episodically, 
its levels measured during the day may possibly be 
beyond the upper limit of normality for a particular 
laboratory in healthy individuals (1,3). Therefore, an 
elevated PRL level should be confirmed at least once 
(33) unless the PRL levels are clearly elevated (> 80-100 
ng/mL) (1). Nevertheless, according to the guidelines 
of the Endocrine Society, a single PRL level above 
the upper limit of normal confirms the diagnosis of 
hyperprolactinemia, as long as the serum sample was 
obtained without excessive venipuncture stress (4).
COMMENT 1: As PRL is secreted in a pulsatile 
manner and as venipuncture stress can increase PRL 
levels, we suggest that an elevated PRL level should 
be confirmed at least once, unless the PRL levels are 
clearly elevated (> 80-100 ng/mL). 
COMMENT 2: Vigorous exercise and nipple 
stimulation should be avoided for at least 30 minutes 
before checking PRL levels as they may result in PRL 
elevation.
1.2 Accuracy of prolactin levels
The magnitude of PRL elevation can be useful in 
determining the etiology of hyperprolactinemia 
because the highest values are observed in patients 
with prolactinomas (1-5,33,34). For example, levels > 
250 ng/mL are highly suggestive of the presence of 
a prolactinoma (3-5), although they may occasionally 
be found in other conditions (1,34), as commented 
on below. In contrast, most patients with stalk 
dysfunction (pseudoprolactinomas), drug-induced 
hyperprolactinemia or systemic diseases present 
with PRL levels < 100 ng/mL (1,4,34). However, 
exceptions to these rules are not rare (1,34).
In patients with prolactinomas, circulating PRL 
levels usually parallel the tumor size (1,4,7). Indeed, 
microprolactinomas (MIC) (diameter < 10 mm) 
usually result in PRL levels of 100-200 ng/mL, but 
not infrequently, they may be < 100 ng/mL, and 
occasionally reach 500 ng/mL or more (1,33,34). 
Macroprolactinomas (MACs) (diameter ≥ 10 mm) are 
typically associated with PRL values > 250 ng/mL (4-7). 
In the vast majority of patients with giant prolactinomas 
(maximum diameter ≥ 4 cm), PRL levels will be > 
1000 ng/mL (35,36). On the other hand, artificially 
low PRL levels may result from the so-called “hook 
effect”, which should be considered in all cases of large 
(≥ 3 cm) pituitary macroadenomas associated with 
normal or mildly elevated PRL levels (< 200 ng/mL) 
(1,37-39), as commented on below. Patients harboring 
cystic MACs may also present with mild PRL elevation 
(1-3). 
The Brazilian Multicenter Study on 
Hyperprolactinemia (BMSH) analyzed 1234 patients 
whose results are presented in Figure 1 and Table 2 (34). 
In this study, only patients harboring prolactinomas 
presented with PRL values ≥ 500 ng/nL (34). 
1.2.1 How do PRL levels behave in cases of 
pseudoprolactinomas?
In patients with “pseudoprolactinomas”, whose 
main etiology isa nonfunctioning pituitary adenoma 
(NFPA), hyperprolactinemia results from compression 
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Figure 1. PRL levels according to the etiology of the hyperprolactinemia in the Brazilian multicenter study on hyperprolactinemia (Adapted from Ref. 34).
Table 2. Prolactin levels (ng/mL) according to the etiology of the 
hyperprolactinemia in the Brazilian Multicenter Study on Hyperprolactinemia 
Etiology N (%) Mean PRL (range) (ng/mL)
Macroprolactinomas 250 (20.2) 1422.9 ± 3134.7 (108-21,200)
Microprolactinomas 444 (36) 165.6 ± 255.1 (32-525)
Idiopathic 45 (3.6) 163.9 ± 81.8 (46-328)
Macroprolactinemia 115 (9.3) 119.5 ± 112.9 (32.5-404)
Drug-induced 180 (14.6) 105.1 ± 73.2 (28-380)
Acromegaly 40 (3.2) 99.3 ± 57.4 (28-275)
NFPA 82 (6.6) 80.9 ± 54.5 (28-490)
Primary hypothyroidism 78 (6.3) 74.6 ± 42.4 (30-253)
NFPA: Non-functioning pituitary adenomas. Adapted from Ref. 34.
called disconnection hyperprolactinemia is thought to 
result from loss of the inhibitory effect of dopamine 
on PRL secretion (19). NFPAs represent the principal 
differential diagnosis of macroprolactinomas, as 
they require distinct treatments and have a distinct 
natural history and prognosis (1,40). The term 
pseudoprolactinomas also includes other conditions 
such as craniopharyngiomas, Rathke´s cleft cysts, 
sarcoidosis, Langerhans-cell histiocytosis and metastasis 
(19,40).
Based on a large series of histologically confirmed 
cases (n = 226) with NFPA, serum PRL > 2000 mIU/L 
(> 95 ng/mL) is almost never (< 2%) encountered in 
these patients (41). Accordingly, in a recent study, 
among 64 patients with immunohistochemically 
confirmed NFPAs, PRL levels ranged from 33 to 
250 ng/mL (~80% < 100 ng/mL) (42) By contrast, 
in BMSH, among 82 patients with NFPA, PRL levels 
ranged from 28 to 490 ng/mL (< 100 ng/mL in 
82%); however, not all patients had been submitted to 
immunohistochemical evaluation (Table 3) (34).
COMMENT 3: In cases of non-functioning 
pituitary adenomas, hyperprolactinemia results 
from stalk compression, and thus, prolactin (PRL) 
levels are modestly elevated (< 100 ng/mL) in 
the great majority of cases. Values > 250 ng/mL 
are exceedingly rare. By contrast, in patients with 
macroprolactinomas, PRL levels are usually > 250 
ng/mL, and not infrequently, they exceed 1000 
ng/mL. However, PRL levels may be misleadingly 
low due to the hook effect or in patients with cystic 
macroprolactinomas.
1.2.2 How do PRL levels behave in cases of drug-
induced hyperprolactinemia?
The most common cause of non-physiological 
hyperprolactinemia is the use of drugs, which 
act through different mechanisms: increased 
transcription of the PRL gene (estrogens), antagonism 
of the dopamine receptor (risperidone, haloperidol, 
metoclopramide, domperidone, sulpiride, etc.), 
dopamine depletion (reserpine, methyldopa), inhibition 
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heroin, morphine, enkephalin analogs, etc.), inhibition 
of dopamine reuptake (tricyclic antidepressants, 
cocaine, amphetamine, monoamine oxidase inhibitors), 
inhibition of serotonin reuptake (opiates, fenfluramine, 
fluoxetine, sibutramine), etc. (1,2,42-47) (Table 3).
Table 3. Drug-induced hyperprolactinemia
Antipsychotics
• Typical – Phenothiazines; butirophenones; thyoxanthenes
• Atypical – Risperidone; molindone; amisulpride; quetiapine; olanzapine
Antidepressants
• Tricyclics – Amitriptyline; desipramine; clomipramine
• MAO inhibitors – Pargyline; clorgyline
• SSRIs – Fluoxetine; citalopram; paroxetine
Antihypertensive drugs




• Metoclopramide; domperidone; bromopride
Others
• Estrogens; anesthetics; cimetidine; ranitidine; opiates; methadone; 
morphine; apomorphine; heroin; cocaine; marijuana; alcohol; sibutramine, 
etc.
MAO: monoamine oxidase; SSRIs: selective serotonin re-uptake inhibitors. Adapted from Refs. 
1, 2, and 3.
In the Brazilian Multicenter Study on 
Hyperprolactinemia (BMSH), antidepressants and 
neuroleptics (in monotherapy or in combination) were 
the culprits in a large majority of the cases (82.2%) 
(34). Among antipsychotics, the most frequently 
involved drugs were haloperidol, phenothiazines, 
and risperidone, while tricyclic drugs were the main 
representants among the antidepressants (34). Other 
studies found the following rates of hyperprolactinemia 
associated with each therapeutic drug class: 31% for 
neuroleptics, 28% for neuroleptic-like drugs, 26% 
for antidepressants, 5% for H2-receptor antagonists, 
and 10% for other drugs (45). In one group of 106 
patients receiving antipsychotics, hyperprolactinemia 
was present in 81%, 35%, 29%, and 38% of patients 
taking risperidone, olanzapine, ziprasidone, and typical 
antipsychotics, respectively (46). 
The newer atypical antipsychotics (AAPs) are 
characterized by increased antipsychotic efficacy and 
fewer neurological and endocrine related side-effects 
compared to classical antipsychotic drugs (45,46). 
With the exception of risperidone, amisulpride and 
molindone, which are often associated with high 
PRL levels (45), most of the AAPs elicit a poor 
hyperprolactinemic response or no hyperprolactinemia 
at all (43,45,46). Furthermore, the use of drugs such 
as quetiapine and aripiprazole (a dopamine partial 
agonist) was shown to be associated with resolution of 
the hyperprolactinemia induced by other AAPs (48). 
Moreover, decreased PRL levels were also reported 
when aripiprazole was used as adjunct therapy to 
risperidone (49).
Antidepressants induce hyperprolactinemia in a 
small proportion of patients, but they rarely elevate 
PRL to a significant degree (46). Among 80 patients 
treated with fluoxetine, only 10 (12.5% developed 
hyperprolactinemia, with 38 ng/mL being the highest 
PRL level (50). Atypical antidepressants, including 
bupropion and mirtazapine, appear to have no effect 
on PRL levels (44,47). 
 Although PRL elevation is usually mild (25-100 
ng/mL) in cases of drug-induced hyperprolactinemia, 
it is also highly variable. Indeed, metoclopramide, 
risperidone, and phenothiazines can lead to prolactin 
levels > 200 ng/mL (1,43-46). Among 180 cases 
enrolled in the BMSH, most (64%) presented with 
PRL levels < 100 ng/mL, but in 5%, they exceeded 
250 ng/mL (range, 28-380; mean, 105.1 ± 73.2) 
(Table 3) (34). Interestingly, PRL levels of 720 ng/mL 
were recently reported in a young lady who had been 
treated with domperidone for 3 months. Following 
domperidone discontinuation, PRL fell to the normal 
range (51).
COMMENT 4: Although drug-induced 
hyperprolactinemia is usually associated with PRL 
levels < 100 ng/mL, they are largely variable and may 
overlap those found in patients with prolactinomas.
1.2.3 How do the hook effect and linearity issues in PRL 
assays impact our practice?
Immunometric assays have greatly improved the 
sensitivity of PRL and other hormone measurements. 
They are usually performed through capture 
antibodies that are immobilized in a solid phase, and 
a second antibodyis labeled a signal generator. These 
antibodies bind to different epitopes of the PRL to 
be quantified, thus forming a “sandwich” test using 
either a fluorescent or chemiluminescent marker. The 
relative antigen-to-antibody proportion influences 
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formation of the immunocomplexes. Thus, extremely 
high concentrations of PRL can simultaneously saturate 
both the capture and the labeled antibody when only 
a few PRL molecules are actually bound in a sandwich 
complex to be quantified by the test. In that situation, 
most of the PRL molecules are bound to just one 
antibody instead and are subsequently washed away 
(Figure 2). Therefore, falsely low results are reported, 
and the correct result for the PRL concentration is much 
higher than reported. This artifact is called a high-dose 
hook effect, also known as the prozone phenomenon, 
and the reported results are usually within or, more 
often, slightly above the manufacturer´s reference 
range (52,53). 
and its reported levels of hook effect by the respective 
manufacturer, dilutions may occasionally start at 1:10. 
For instance, considering an assay in which, according 
to its manufacturer, the hook effect is not supposed 
to be induced up to a PRL value of 20,680 ng/mL, 
this theoretically means that a starting dilution of 1:10 
should be sufficient enough to detect the phenomenon, 
as it is very improbable to have a PRL value higher than 
200,680 ng/mL (53). In this regard, it is noteworthy 
that unnecessary dilutions usually cause a loss of accuracy 
in measurements. Fortunately, with the newer assays, 
extremely high levels of PRL are usually necessary to 
hook the assay, and this fact has dramatically decreased 
the incidence of this phenomenon (53,54).
Interestingly, the hook effect has often been 
confused with assay linearity problems by clinicians 
(54). In a given assay with a reportable PRL ranging 
from 0.25-200 ng/mL according to the manufacturer, 
PRL samples coming from patients with untreated 
macroprolactinomas may often fall out of this 
reportable range, even when an automatic dilution of 
1:10 is superimposed. In this case, it is common that the 
laboratory releases a result of “> 2000 ng/mL”, and it 
seems that they are not aware of the importance of exact 
quantification of the result. Therefore, clinicians must 
refrain from starting treatment until the laboratory re-
assays the sample at further dilutions, even if it has to be 
performed manually, and up to the point that the linear 
range of the assay is reached. Otherwise, the observed 
effect of a treatment may be misled due to an inexact 
reported measurement (53,54).
COMMENT 5: The hook effect should be 
considered in every patient presenting with a large 
(≥ 3 cm) pituitary macroadenoma and prolactin levels 
within the normal range or only modestly elevated. 
1.3 Macroprolactinemia screening: routinely or just 
in asymptomatic individuals?
Macroprolactinemia is a condition where more than 
60% of circulating PRL is made up of macroprolactin 
(1,29). In most of the in vitro studies, macroprolactin 
was shown to display low biological activity (28,29,55). 
This is corroborated by the finding that in most series 
with macroprolactinemia, individuals are pauci- or 
asymptomatic (56,57), with no need to perform sellar 
imaging (58) or specific treatments (58,59). Others 





Antigen concentration extremely high
Figure 2. Schematic depiction of “hook effect.” Left, Extremely high 
antigen concentrations saturate both capture and signal antibodies and 
prevent “sandwich” formation. Right, When liquid phase is discarded, 
most of the antigen is lost with the signal antibody; thus, antigen 
concentration is measured as low (Adapted from Ref. 39).
The hook effect differs between the different assay 
systems used in clinical practice. Dilution of the sample 
at 1:100 is the test of choice to unmask this hook effect 
(1,4). Indeed, this step will result in a dramatic rise 
in PRL levels if the patient has a macroprolactinoma, 
remaining low in cases of non-functioning pituitary 
adenomas (1,4,37,38).
Physicians should keep in mind that laboratories 
cannot dilute all samples on a routine basis to rule out 
the hook effect. Thus, it is extremely important that 
they are aware of the phenomenon so they do not 
forget to order dilution for all PRL samples suspected 
to be overconcentrated. In clinical practice, this means 
that dilutions must be ordered for PRL measurements 
in all patients with macroadenomas ³ 3 cm and initial 
PRL levels < 200 ng/mL, even if the PRL levels are 
normal (1,2,38). However, it is relevant to mention 
that dilutions ordered by physicians are performed at 
the discretion of laboratory workers. This means that, 
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be blocked by modification of the tertiary structure of 
the original molecule (60).
However, there are individuals who, despite 
increased macroprolactin, also present with high 
levels of monomeric PRL, leading to “true” 
hyperprolactinemia with clinical symptoms and the need 
foran etiologic diagnosis for the proper management 
of hyperprolactinemia (59). Moreover, the presence 
of symptoms could result from the concomitance of 
macroprolactinemia with other conditions, such as 
polycystic ovary syndrome (61), idiopathic galactorrhea 
(1,2), or psychogenic erectile dysfunction (62). 
Assaying serum PRL before and after precipitation 
with polyethylene glycol (PEG) is the most 
used method for screening macroprolactinemias 
due to its low cost and easy workability (63). 
Theoretically, macroprolactin is precipitated with 
PEG, and only monomeric PRL will be recovered 
in the supernatant. However, some monomeric PRL 
also suffers precipitation, hence the need for the 
standardization of normal monomeric PRL values 
after PEG precipitation (58,60). Recoveries < 40% 
are indicative of the predominance of macroprolactin, 
whereas recoveries > 60% point to the diagnosis of 
monomeric hyperprolactinemia (56,58). Overall, 
PEG precipitation enables the correct diagnosis of 
macroprolactinemia in at least 80% of cases (56,63). 
The gold standard diagnostic test is the separation of 
isoforms by gel filtration, which correlates well with 
the PEG precipitation and is the only way of assessment 
when screening with PEG is inconclusive (58,63). 
However, it is an expensive and time-consuming 
method that cannot be used routinely. 
It is noteworthy that different assays recognize 
macroprolactin differently (64). It has been 
demonstrated that some of the new assays show lower 
cross-reactivity with macroprolactin; however, the 
number of samples defined as macroprolactin is still 
significant (65).
Hyperprolactinemia related to macroprolactin 
may be due to its lower renal clearance, longer half-
life and lower capability to activate hypothalamic 
dopaminergic tone, which negatively regulates the 
secretion of pituitary prolactin (5). The frequency 
of macroprolactinemia in the general population was 
shown to be 0.2% in women from Scandinavia (66) and 
3.7% in a total of 1330 Japanese hospital workers of 
both genders (67), whereas among hyperprolactinemic 
individuals, it ranged from 8 to 42%, with a mean of 
19.6%, in 8 European series (56,68-75). The study 
population may explain the variation in the frequency of 
macroprolactinemia in hyperprolactinemic individuals. 
As an example, two Brazilian studies have shown 
frequencies of 16.5% in 115 consecutive patients with 
hyperprolactinemia (76) and 46% in 113 cases from 
a reference laboratory (58). This high frequency of 
macroprolactinemia becomes an important issue in 
clinical practice: what is the probability with an additional 
assessment and treatment in an individual presenting 
with macroprolactinemia? Should all individuals with 
hyperprolactinemia be actively investigated for the 
presence of macroprolactinemia? 
The request for serum PRL assessment occurs 
in two scenarios. At first, there are complaints 
related to hyperprolactinemia, such as galactorrhea, 
hypogonadism and infertility, leading to serum 
PRL measurement. If laboratory tests confirm the 
clinical suspicion of monomeric hyperprolactinemia, 
macroprolactinemia screening is not indicated, and it 
is recommended to proceed to the usual investigation 
of physiological, pharmacological and pathological 
causes of hyperprolactinemia for proper handling 
of the case. In the second scenario, serum PRL 
evaluation is requested in the absence of complaints 
related to hyperprolactinemia. In this situation, facing 
hyperprolactinemia in an asymptomatic individual, 
macroprolactinemia screening is always indicated. 
If positive and monomeric PRL levels are normal, 
it should guide the patient that there is no need 
for further investigation, follow-up or treatment, 
due to the benign nature of the condition. If the 
screening with PEG is inconclusive, one may proceed 
to gel-filtration chromatography, or if the latter is 
unavailable, be guided by the clinical picture. If 
the macroprolactin result is negative, investigate 
hyperprolactinemia as usual. A flowchart for the 
management of macroprolactinemic individuals is 














Figure 3. Flowchart to the management of patients with macroprolactinemia 
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Some authors advocate routine macroprolactin 
screening as a cost-effective procedure (56,76-78), and 
others allow screening to rule out macroprolactinemia 
and investigate other conditions that justify symptoms 
(79). In a study conducted in a Brazilian reference 
laboratory, there was more cost in searching for 
individuals with true hyperprolactinemia, but screening 
macroprolactinemia did not prevent investigation 
and inappropriate treatment, pointing to the need 
for the dissemination of medical knowledge about 
macroprolactinemia (80). By contrast, according to 
some studies, the detection of macroprolactin may 
change the initial diagnosis in a significant proportion 
of patients. Indeed, in three series (73,74,81), 
macroprolactinemia was encountered in 25 to 68.3% 
(mean, 42.3%) of patients with apparent idiopathic 
hyperprolactinemia (IH). Moreover, the diagnosis 
of PRL-secreting pituitary microadenoma shifted to 
non-secreting pituitary microadenoma in 10 of 49 
patients (20%) reported by Donadio and cols. (73). 
Thus, macroprolactinemia may occasionally represent a 
relevant cause of misdiagnosis, unnecessary investigation 
and inappropriate treatment (73,74,81). Conversely, 
PRL should never be measured in asymptomatic 
patients, in order to avoid the unnecessary detection of 
macroprolactinemia cases (1,5).
Concerning the natural history of macro-
prolactinemia, macroprolactinemic subjects usually 
display persistent macroprolactinemia without the 
development of raised free PRL (82). However, 
during follow-up, hyperprolactinemia may develop 
in macroprolactinemic subjects who were initially 
normoprolactinemic along with an increase in anti-
PRL autoantibody titers (82).
Overall, symptoms related to hyperprolactinemia 
(galactorrhea, menstrual disorders and sexual 
dysfunction) have been reported in up to 45% of 
patients with macroprolactinemia (56,58,69,70,73, 
74,76,83,84). As mentioned, this would mostly 
result from the concomitance with monomeric 
hyperprolactinemia (74,75,85) or other disorders, 
such as polycystic ovary syndrome (1,61,62). Of 
note, the finding of both galactorrhea and menstrual 
disorders is rare in macroprolactinemia (83,84).
In most patients with macroprolactinemia, PRL 
levels are < 100 ng/mL, but they are highly variable: 
from 20-663 ng/mL (mean, 61 ± 66; < 100 ng/mL 
in approximately 91% of cases) (83), to 119.5 ± 112.9 
(range, 32.5-404; < 100 mg/L in 74%) among 115 
patients in the BMSH (33). In most studies, PRL levels 
were lower in macroprolactinemic patients than in 
those with monomeric hyperprolactinemia, but there 
was a great overlap between groups (34,56,63,69,83). 
Moreover, MRI abnormalities (e.g., macroadenomas 
and, mostly, microadenomas or an empty sella) may be 
found in approximately 20-25% of macroprolactinemic 
patients (69,70,73,74,84).
COMMENT 6: Macroprolactinemia is, in most 
cases, a laboratory diagnostic pitfall, with a mean 
frequency of ~20% among hyperprolactinemic 
subjects. Clinical, radiological and laboratory features 
cannot be used reliably to differentiatemonomeric 
hyperprolactinemia from macroprolactinemia. The 
screening for macroprolactin is mostly indicated for 
asymptomatic hyperprolactinemic patients, subjects 
with apparent idiopathic hyperprolactinemia, 
and any patient without an obvious cause for the 
hyperprolactinemia.
TREATMENT OF HYPERPROLACTINEMIA AND 
PROLACTINOMAS
The ideal treatment of hyperprolactinemia depends on 
its etiology and may include, for instance, L-thyroxine 
replacement in patients with primary hypothyroidism, 
dopamine agonists (DAs) for prolactinomas, and drug 
withdrawal in cases of drug-induced hyperprolactinemia 
(2-7). By contrast, macroprolactinemia does not need 
to be treated (5,24,25). 
Current available therapeutic options for 
prolactinomas include surgery, pituitary radiation 
therapy and pharmacotherapy with dopamine agonists 
(DAs) (19). DAs are the gold standard treatment 
for prolactinomas, as their use controls hormonal 
secretion and tumor growth in approximately 80% 
of cases (8). Among DAs, bromocriptine (BRC) 
and cabergoline (CAB), both of which are ergot 
derivatives, are the most commonly used worldwide. 
Quinagolide is available in some European 
countries. Cabergoline (CAB), a specific agonist 
of the dopamine receptor type 2 (D2R), is the first 
choice because of its better tolerability and greater 
efficacy in inducing PRL normalization and tumor 
shrinkage (Figures 4 and 5) (Table 4) (19,86-89). 
Bromocriptine use leads to normal serum PRL 
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2. CONTROVERSIAL ISSUES REGARDING TREATMENT
In this topic, we will cover challenging or controversial 
aspects related to the treatment of prolactinomas 
and the management of psychotropic-induced 
hyperprolactinemia. 
2.1 How to manage the resistance to dopamine 
agonists? 
Different arbitrary concepts have been proposed for 
the definition of resistance to dopamine agonist (DA) 
therapy (2,4,88-91). Currently many experts have 
adopted the definition suggested by Molitch, which 
includes failure to normalize PRL levels and to decrease 
macroprolactinoma size by ≥ 50% with maximal 
conventional doses of medication (7.5 mg/day of 
bromocriptine or 2.0 mg/week of cabergoline) (89,90). 
Bromocriptine (BCR) fails to normalize prolactin levels 
in approximately one-quarter of patients; cabergoline 
(CAB), in 10-15%. BCR fails to decrease prolactinoma 
size by at least 50% in approximately one-third of the 










































   





















Microprolactinoma (n = 121) Macroprolactinoma (n = 117)
 
 

















































Figure 4. Comparison of cabergoline (CAB) and bromocriptine (BCR), 
concerning efficacy and tolerability (Adapted from Ref. 34).
Figure 5. Comparative efficacy of CAB and BCR in inducing tumor shrinkage 
in naïve patients with macroprolactinomas (Adapted from Ref. 34). 
Figure 6. Efficacy of cabergoline on the normalization of PRL levels in 238 
patients with prolactinomas. BCR: bromocriptine (Adapted from Ref. 34). 
macroprolactinomas, whereas with CAB, this goal 
is achieved in 85% of patients (3,86-88). CAB 
effectiveness is higher in naïve patients, but the drug 
is also very effective in patients with intolerance or 
resistance to BCR (Figures 6 and 7) (34,88). The 
better performance of CAB probably results from 
its better tolerance and higher affinity for D2R 
(10,19,88). 
Figure 7. Concerning macroprolactinoma shrinkage, cabergoline is 
effective not only in naive patients but also in those previoiusly treated with 
bromocriptine (BCR) (Adapted from Ref. 34). 
Table 4. Comparative efficacy of cabergoline (CAB) and bromocriptine 
(BCR) among patients with macroprolactinomas from the Brazilian 
Multicenter Study on Hyperprolactinemia 
Outcome CAB  (n = 117)
BCR 
(n = 133) p-value
PRL normalization 77.8% 59.4% 0.042
Tumor reduction > 50% 80% 58.7% 0.048
Complete tumor disappearance 57.5% 34.7% 0.034
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Pathogenetic mechanisms 
There are a number of potential mechanisms to 
explainresistance to DAs. Drug absorption or drug 
affinity to D2R are not involved (90). DA resistance 
is rather associated with a decrease in D2R gene 
transcription, resulting in a 4-fold decrease in the 
number of D2Rs on the cell membrane (92,93). 
Moreover, there is a decrease in the G protein that 
couples the D2R to adenylyl cyclase, further decreasing 
the ability of dopamine to inhibit PRL secretion (90). 
Patients who initially respond to a DA may rarely 
become resistant to these drugs at a later point in time 
(90). Most commonly, this is due to noncompliance. 
Rarely, there may be malignant transformation of a 
prolactinoma (94). In some cases, the development of 
DA resistance is due to the concomitant use of hormone 
replacement therapy with estrogen or testosterone (95).
Treatment
The approaches for patients with resistance to DA 
therapy include (1) switching to another DA; (2) raising 
the dose of the DA beyond conventional doses if the 
patient continues to respond and tolerate; (3) surgical 
tumor resection; (4) radiotherapy; and (5) experimental 
treatments with other drugs (34,88,90,96,97).
Switching to another DA
Most of the data regarding switching dopamine agonists 
in resistant patients address switching from BCR to 
CAB. CAB is effective in normalizing PRL levels in 
approximately 50-80% of patients resistant to BCR, 
and up to 70% respond with some tumor size change 
(30,90,96,97). It is not clear why CAB should be so 
effective in patients resistant to BCR, but this may be due 
to cabergoline’s possessing a higher affinity for dopamine 
binding sites, a longer time occupying the receptor, and a 
slower elimination from the pituitary (90,97). By contrast, 
the response to BCR in a patient resistant to CAB is much 
more rare and has only been reported twice (90,98).
Raising the dose of the DA beyond conventional doses 
As long as there is a continued response and no adverse 
effects from higher doses, there is no reason not to 
continue to increase the CAB dose (90). There is, however, 
a concern regarding the risk of cardiac valvulopathy 
induced by high doses of CAB (see below) (88,90). 
Using an individualized, stepwise approach of dose 
titration of CAB, Ono and cols. (99) documented 
that 25 of 26 patients (96.1%) considered to have DA 
resistance, achieved normalization of the PRL levels 
within 12 months, with a mean dose of CAB of 5.2 ± 0.6 
mg per week (range 3-12 mg/week). The rate of PRL 
normalization gradually increased to 35, 73, and 89% 
at 3, 6, and 9 mg/week, respectively, finally reaching 
96% at the highest dose of 12 mg/week (99). DiSarno 
and cols. (100) found that doses > 2.0 mg/week (up to 
7 mg/week) of CAB werestill unable to normalize PRL 
levels in 18% of patients with macroadenomas and 10% 
of those with microadenomas. More recently, Vilar and 
cols. (101) prospectively evaluated the management 
of 25 prolactinomas refractory to CAB 3 mg/week by 
progressively increasing the CAB dose as needed and 
tolerated, every 3 months, up to 9 mg/week. Overall, 
normalization of PRL levels was achieved in 18 patients 
(72%), as follows: in 3 (12%) patients, with up to 4 
mg/week; in 9 (36%) patients, with 5 mg/week; and 
in 6 (24%) patients, with 6-7 mg/week. No patients 
benefitted from doses > 7 mg/week. CAB was well 
tolerated, and no significant echocardio graphic valve 
abnormalities were detected (101).
Debulking surgery 
Patients can always undergo transsphenoidal surgery if 
their tumor is potentially resectable and an experienced 
neurosurgeon is available (4,90). There is also some 
evidence that debulking surgery may improve the 
response to DA (6,102-104). Of 61 patients resistant to 
either BCR or CAB, Hamilton and cols. (102) reported 
that surgery resulted in a normalization of PRL in 36% 
without dopamine agonist medication and in 15% with 
medication. Similarly, Primeau and cols. (102) found 
in 26 patients resistant to BCR, quinagolide or CAB 
that surgery resulted in a normalization of PRL in 42% 
without medication and in 27% with medication. In the 
European Multicenter Study, the rate of postoperative 
normalization of PRL was only 7.8% without medication 
and 5.3% with medication (104).
Radiotherapy 
Among the functioning pituitary tumors, prolactinomas 
seem to be the less responsive to radiotherapy (see 
below). Indeed, although it can also be effective in 
controlling tumor growth, its efficacy in restoring PRL 
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Other drugs 
Of note, if one is dealing with microprolactinomas 
resistant to DAs, hormonal replacement therapy is 
often all that is necessary for men and premenopausal 
women not willing to conceive (4,19,90). 
Estrogens may cause a decrease in the effectiveness 
of dopamine agonists through multiple mechanisms, 
including direct effects on PRL gene transcription 
(105), stimulation of mitotic activity (106), and a 
decrease in the number of D2 receptors on the lactotroph 
cell membrane (107). Moreover, estrogen may block 
apoptosis (108). Thus, reducing endogenous estrogens 
in resistant prolactinomas through the use of SERMs 
in women or aromatase inhibitors in men might be 
an interesting experimental approach. Accordingly, a 
few patients with “bromocriptine resistant” invasive 
macroprolactinomas have been shown to respond with 
a decrease in tumor size and a lowering of PRL levels 
when tamoxifen was added (90,109). The use of the 
SERM clomiphene was also shown to be effective in 
the recovery of hypogonadism in prolactinoma patients 
who persisted with low testosterone levels despite 
maximal doses of DA (110,111). In addition, the 
successful use of anastrozole, an aromatase inhibitor, 
was recently reported in two males with DA-resistant 
prolactinomas (90,112). 
Somatostatin analogs generally are not useful for 
PRL-secreting tumors (90), and there have been few 
reports on the successful combination therapy of 
octreotide (113) or lanreotide (114) and cabergoline 
in cases of DA-resistant tumors. The somatostatin 
receptor subtype 5 (SSTR5) is the most important 
with respect to the regulation of PRL secretion 
(115). Therefore, as pasireotide only has substantial 
activity at SSTR5 (116), it would be potentially 
more useful than the SSTR2-agonists octreotide and 
lanreotide in patients with aggressive DA-resistant 
prolactinomas (90). 
Temozolomide, an oral alkylating agent, has been 
successfully used in the treatment of aggressive or 
malignant pituitary tumors since 2006 (117,118). 
It has also been found to be moderately successful in 
some very aggressive, large DA-resistant prolactinomas. 
Reviewing such cases, Whitelaw and cols. (119) 
found that 12 of 20 (75%) resistant PRL-secreting 
macroadenomas responded to temozolomide. Given 
the toxicity of the drug, its use is generally regarded as 
the therapy of last resort and should only be performed 
after the failure of DAs, surgery and radiotherapy for 
tumor control (90,119). Unfortunately, many of these 
very aggressive tumors escape from the suppressive 
effects of temozolomide after 0.5-2.5 years (90,119).
Other treatment strategies undergoing clinical 
trials are the use of chimeric molecules (somatostatin 
analogues and dopamine D2 receptors) (2,3), PRL 
receptor antagonists (3), and antiblastic drugs, such as 
mTOR and tyrosine kinase inhibitors (3,120).
COMMENT 7: Patients with resistance to 
bromocriptine should be switched to treatment 
with cabergoline (CAB), which leads to prolactin 
normalization in at least 50% of cases. Facedwith 
resistance to CAB, a stepwise increase in the dose 
should be performed first, as long as there is a 
continued response and no adverse effects. This 
approach is successful in at least 70% of patients. 
In our experience, doses > 7 mg/week do not 
provide additional benefits. Debulking surgery may 
improve a response to the dopamine agonist (DA) 
when the medical treatment has failed.Radiation and 
temozolomide can be indicated to control aggressive 
tumor growth even under DA therapy.
2.2 Are there differences in the safety profile of DAs?
DA therapy often precipitates a broad spectrum 
of side effects, more frequently gastrointestinal 
symptoms (e.g., constipation, nausea, vomiting, 
etc.) but also postural hypotension, dizziness and 
headaches, which may range from mild to severe 
(34,88,121). The most common adverse events 
include nausea or vomiting (~35%), headache 
(~30%), and dizziness or vertigo (~25%) (121). 
The safety profile of CAB is similar to that reported 
for BRC, but CAB adverse effects are generally 
less frequent, less severe, and of shorter duration 
(34,88), and they resolve with dose reduction or 
continued use in many patients (34,88,121). The 
rate of treatment discontinuation due to complete 
intolerance is also significantly higher with BCR, 
compared to CAB (~12% vs ~4%) (87). 
Whether CAB is associated with an increased risk of 
clinically relevant cardiac valvulopathy in patients with 
prolactinomas as in those with Parkinson’s disease is 
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2.3 Do dopamine agonists cause psychiatric 
disorders?
Dopamine antagonists (e.g., haloperidol, olanzapine, 
quetiapine, sulpiride) are classically used for the 
treatment of psychiatric disorders such as psychosis 
and schizophrenia due to the supposed dopaminergic 
hyperactivity that occurs in these cases (43,46,47). 
DA treatment exerts the opposite effect to that of the 
dopamine antagonists (7). These agents can rarely cause 
psychiatric adverse side effects, including depression, 
somnolence, anorexia, anxiety, insomnia, impaired 
concentration, nervousness, hallucinations, nightmares, 
psychosis, impulsive control disorders (ICDs), and 
mania (3,5,122-125). The exact incidence of these 
side effects in DA-treated patients is not known but is 
thought to range from less than 1% to 3% (122,123).
ICDs are characterized by difficulties in resisting 
urges to engage in behaviors that are excessive and/
or ultimately harmful to oneself or others and can 
include gambling, kleptomania, intermittent explosive 
disorder, compulsive sexual behavior and compulsive 
buying (126). 
Few reports have been published focusing on 
ICDs and other psychiatric disorders in prolactinoma 
patients treated with CAB (123-133). These reports 
have described disorders such as a first episode of 
mania (123,129); mania with psychotic features in a 
subject with bipolar disorder after starting CAB (125); 
psychosis in a patient with undiagnosed depression 
(126); compulsive gambling one year after starting 
CAB (130); gambling and compulsive sexual behavior 
just after starting CAB (131); psychosis in a patient 
without a previous history of psychiatric disorder three 
months after starting CAB (132); and depression and 
compulsive buying (133). 
In 2011, Martinkova and cols. (128) published a 
review reporting a 10% prevalence of ICD in patients 
on CAB for prolactinoma treatment. In another study, 
males with prolactinomas treated with DAs have been 
reported to be 9.9 times more likely to develop an 
impulse control disorder compared to their counterparts 
with nonfunctioning pituitary adenomas (134). More 
recently, Barake and cols. (135) conducted the only 
randomized study aiming to assess the impact of CAB 
on the appearance of ICDs and concluded that patients 
on CAB (particularly with higher dosages) were more 
susceptible to impulsivity disorders than those not 
taking the drug.
Psychiatric effects of CAB can be modulated by 
P-glycoprotein (P-gp). This protein, encoded by 
the ABCB1 gene (136), is a membrane transporter 
expressed in tumor cells and in normal tissues that acts 
as an efflux transporter in order to transport certain 
substances out of the brain and protect it against 
harmful substances. A recent study showed that CAB 
is a P-gp substrate (137). This study demonstrated that 
ABCB1 gene polymorphisms (with loss of function) 
could explain individual differences in the occurrence 
of central nervous system side-effects, demonstrating a 
future perspective to select patients for CAB treatment 
based on this gene study (137).
COMMENT 8: In susceptible subjects, psychotic 
symptoms and impulsive control disorders may be 
triggered or aggravated by dopamine agonist (DA) 
therapy. It seems therefore important to exclude 
psychiatric disorders before prescribing DAs and to 
carefully follow up patients prone to or with a history 
of psychiatric disorders.
2.4 Risk of heart valvular disease associated with 
dopamine agonists – what is its relevance? 
The main warning signs that cause concerns among 
endocrinologists about a possible association between 
the therapeutic use of dopamine agonists (DAs) with 
heart valvular disease (HVD) emerged from two articles 
published in 2007 involving patients with Parkinson’s 
disease (138,139). In this group of patients, there is 
now strong evidence that treatment with high doses of 
CAB and pergolide (PGL) is associated with a higher 
risk of cardiac valvular regurgitation and moderate 
evidence that treatment with CAB, and the non-ergot-
derived DAs pramipexole is associated with a higher 
risk of heart failure (140). The underlying mechanism 
involves the activation of the 5-hydroxytryptamine 2B 
(5-HT2B) receptors, abundantly expressed on heart 
valves, which induces a cascade of events involving 
mitogenesis, fibroblast proliferation, valve thickening 
and, finally, valvular dysfunction (141,142). DAs bind 
to 5-HT2B receptors with different affinities; for 
instance, CAG and PGL show high affinity and act as 
a potent agonist, whereas bromocriptine (BRC) has 
a lower affinity compared to other DAs (141,142). 
However, there have been case reports and clinical 
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risk of abnormal valvular regurgitation and cardiac and 
non-cardiac fibrotic reactions in patients treated with 
BRC (143,144).
As expected, the findings in patients with Parkinson's 
disease brought an immediate concern about the risk of 
HVD in endocrine patients treated with DAs, especially 
CAB, despite the striking differences between these 
groups that must be highlighted. First, the daily and 
cumulative doses of DAs used in neurology (at least 3 
mg of CAB per day) are approximately 10-fold higher 
than those used in endocrinology (rarely more than 3 
mg of CAB per week) (145). Moreover, most studies 
in Parkinson’s disease predominantly include men 
older than 60 years of agewho are usually on therapy 
with multiple drugs, while patients with endocrine 
abnormalities treated with DAs are predominantly 
young or middle-age women (146). This is important 
because the prevalence of valvular regurgitation 
increases with age and is influenced by gender, body 
mass index and hypertension (146,147). Another factor 
to be considered is the impact of examiner bias in the 
results, as shown in the study by Gu and cols. (148). 
In patients with hyperprolactinemia, most cross-
sectional studies were dedicated to investigating the role 
of CAB in HVD. A meta-analysis of seven observational 
studies with 1,398 individuals found an increased risk 
of mild-to-moderate tricuspid valve regurgitation in 
hyperprolactinemic patients taking CAB. No significant 
differences were observed in mitral or aortic valve 
regurgitation (149). Another recent systematic review 
analyzed data from 21 studies and from 40 patients 
followed by the authors (150). Utilizing the precise 
definition of CAB-associated valvulopathy as the triad 
of moderate or severe regurgitation associated with 
a restricted and thickened valve, clinically relevant 
disease was identified in only two out of 1,811 patients, 
resulting in a prevalence of 0.11% (150). The authors 
of this study also prospectively assessed 40 patients 
with prolactinoma taking cabergoline. Cardiovascular 
examination before echocardiography detected an 
audible systolic murmur in 10% of cases (all were 
functional murmurs), and no clinically significant 
valvular lesion was shown on echocardiogram in the 
90% of patients without a murmur (150).
A Brazilian study by Boguszewski and cols. (151) 
was the first to include a group of prolactinoma 
patients treated with BRC for comparison. Notably, a 
higher prevalence of trace tricuspid regurgitation was 
observed in patients taking BRC, while more prevalent 
trace-to-mild tricuspid and trace mitral regurgitation 
and a higher mitral tent area were observed in CAB 
users; nevertheless, all these echocardiographic findings 
were not clinically significant (151). This observation 
was confirmed in a subsequent study in which an 
increased prevalence of subclinical HVD in patients 
with prolactinomas on long-term treatment with either 
BRC or CAB was reported (152).
Beyond the cross-sectional investigations, 
longitudinal studies have shed light on the potential 
damage caused by DAs to cardiac valves. Delgado 
and cols. (153) followed patients with prolactinomas 
treated (n = 45) or not treated (n = 29) with CAB for 
2 years and found an increased prevalence of valvular 
calcification in CAB users that was not accompanied by 
a higher prevalence of valvular dysfunction. Auriemma 
and cols. (154) concluded that 5 years of CAB therapy 
in prolactinomas does not increase the risk of significant 
cardiac valve regurgitation. Similarly, 19 patients 
with prolactinomas were followed in Curitiba, Brazil, 
during 5 years of continuous treatment with DAs. 
Neither a significant change in valvular regurgitation 
grades nor symptomatic disease was observed in the 
follow-up (155). Population-based studies have also 
confirmed the safety of CAB in endocrine patients. A 
nationwide cohort study carried out in Denmark did 
not support that hyperprolactinemia or its treatment is 
associated with an increased risk of clinically significant 
HVD (156). In a multi-country, nested case-control 
study involving data from the United Kingdom, Italy, 
and the Netherlands, CAB was associated with an 
increased risk of HVD in Parkinson’s disease but not 
in hyperprolactinemia (157), confirming the role of 
high cumulative doses in the development of valvular 
dysfunction and the safety of long-term use of low 
cumulative doses. 
In two studies involving 51 prolactinoma patients 
considered to be resistant to standard doses of CAB, no 
significant echocardio graphic valve abnormalities were 
detected despite the use of doses ranging from 3 to 12 
mg/week (99,110).
The absence of a detrimental effect of CAB therapy 
on cardiac valves has also been noticed in a longitudinal 
study in patients with acromegaly (158). 
The findings of the abovementioned studies 
challenge the US Food and Drug Administration 
(FDA) advice that patients with prolactinoma treated 
with CAB should have an annual echocardiogram 
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conventional doses of cabergoline, i.e., up to 2 mg/
week, usually used in patients with prolactinomas, 
there does not appear to be any increased risk of 
cardiac valve abnormalities (90,145,156). However, 
as it is uncertain at what dose level these valve 
effects become significant, some experts recommend 
assessing all patients receiving > 2 mg/week with an 
echocardiogram on a yearly basis (90). More recently, 
based on the findings of their systematic review, Caputo 
and cols. (150) proposed that such patients should be 
screened by a clinical cardiovascular examination and 
that echocardiograms should be reserved for patients 
with an audible murmur, those treated for more than 
5 years at a dose of more than 3 mg per week, or those 
who maintain cabergoline treatment after the age of 50 
years. Nevertheless, special attention should be given 
in interpreting echocardiographic findings in older 
individuals, as highlighted by some authors (146,147).
Subclinical valvular abnormalities detected by 
echocardiography are not an indication for cessation 
of the therapy (121,154). Importantly, if valve lesions 
are detected or progress during follow-up, further 
evaluation is indicated to distinguish CAB-induced 
etiologies from other causes of valvulopathies. In 
such cases, therapy may be interrupted, reduced or 
maintained based on clinical judgment and discussion 
with the patient (121,150,154).
COMMENT 9: Current available data do not support 
major concerns about the risk of valvulopathy in 
patients with hyperprolactinemia or other endocrine 
diseases who are chronically treated with DAs in 
standard doses. Thus, an echocardiogram evaluation 
would not be recommended for patients receiving 
cabergoline at doses up to 2 mg/week.
 
2.5 Withdrawal of the dopamine agonist – Why, 
when, how and how often?
Why, when and how? 
Although it is well known that prolactinomas respond 
very well to DAs, the optimal duration of treatment is 
still not clear (4,6,10). Despite the need for long-term 
therapy, withdrawal of treatment should be considered 
because of the adverse effects of medical treatment, 
potential long-term consequences in cardiac valves, and 
treatment costs (4,6,88). 
Studies on persistent normoprolactinemia after DA 
withdrawal have been published since 1979 (159). In 
2002, a Brazilian study by Passos and cols. (160) showed 
a remission rate of 20.6% after BCR discontinuation. In 
2003, a landmark prospective study by Colao and cols. 
(161) demonstrated that CAB could be successfully 
withdrawn in 70% of patients with a MIC and 64% 
of those harboring a MAC (161). An extension of 
this study to 8 years documented remission rates of 
66 and 47%, respectively (162). The higher success 
rates of this study were attributed to stricter selection 
criteria for CAB withdrawal, including a prolonged 
period of normoprolactinemia during treatment and 
a significant tumor size reduction (161,162). Since 
2003, several studies have evaluated the recurrence 
rates of hyperprolactinemia after DA withdrawal with 
variable results (162-170).
In a meta-analysis of 19 studies with a total of 743 
patients, the overall remission rate after the withdrawal 
of DA therapy was only 21%, 32% for idiopathic 
hyperprolactinemia, 21% for microadenoma and 16% 
for macroprolactinomas (171). Furthermore, a higher 
rate of remission was found in studies in which CAB 
was used (35% in 4 studies) versus BRC (20% in 12 
studies) (p = 0.07) (171). In studies lasting over 24 
months of treatment, the remission was higher (34%) 
in comparison to studies with a shorter treatment 
duration (16%) (p = 0.01) (153). The remission rate 
was also higher in studies in which agreater than 50% 
reduction of the tumor was achieved in all patients 
prior to discontinuation of therapy (171).
The guidelines provided by the Endocrine Society 
in 2011 recommended that patients who have attained 
normoprolactinemia for at least 2 years and who have 
no visible tumor remnant on MRI may be candidates 
for a gradual DA withdrawal (4).
A meta-analysis from 2015 that only evaluated 
patients submitted to CAB withdrawal found that 
the hyperprolactinemia recurrence rate was 65% by a 
random effects meta-analysis (172). In a random effects 
meta-regression adjusting for optimal withdrawal 
strategies, a CAB dose reduced to the lowest level 
before withdrawal was associated with treatment success 
(p = 0.006), whereas CAB treatment longer than 2 
years showed no trend of effect (p = 0.587). Patients 
who received the lowest CAB dose and presented a 
significant reduction in tumor size before withdrawal 
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In three recent studies, the recurrence rates after 
CAB withdrawal ranged from 27% to 54% (168-170). 
Among 74 patients (19 MACs and 55 MICs) treated 
with CAB for ≥ 3 years, recurrences occurred within 
12 months in 34 (45.9%), regardless of the previous 
duration of CAB therapy (up to 3 yrs, 3 to 5 yrs or > 5 
yrs) or initial adenoma size (168). Among 67 patients 
(23 MACs and 44 MICs), the overall recurrence rate 
was 54% (35% in cases of MIC and 64% in subjects with 
MAC) (169). A higher remission rate was found with 
CAB, compared to BCR (55% vs. 36%) (169). More 
recently, treatment discontinuation was evaluated 
in 11 patients with macroprolactinomas treated 
with CAB for at least 5 years (170). Recurrences of 
hyperprolactinemia were observed in 3 (27%) post-
withdrawal patients at a median time of 3.0 (range; 2.9-
11.2) months, indicating that a high percentage (73%) 
maintained remission for at least 12 months after CAB 
cessation (170). 
How often? 
Two independent studies (173,174) have investigated 
the outcome of a second attempt at CAB withdrawal 
in patients with recurrence of hyperprolactinemia after 
the first withdrawal, receiving additional CAB therapy 
for at least 2 years. The results of these studies have 
demonstrated that a second attempt at CAB withdrawal 
after 2 additional years of therapy may be successful in 
approximately 30% of patients (173,174).
What are the predictors of remission?
Several studies in the literature sought the predictors of 
remission after stopping DAs, but the results of these 
studies have been contradictory (4,6,10,19). Overall, 
parameters more often associated with a successful 
DA withdrawal include suppressed PRL levels, the use 
of low doses of CAB, and lack of a visible tumor on 
MRI before withdrawal. However, hyperprolactinemia 
recurrence was observed even in patients who presented 
with these parameters (168-172). 
In the great majority of studies, patients harboring 
MACs presented a lower risk of hyperprolactinemia 
remission than those with MICs when treatment is 
discontinued (161-169). The same was true when CAB 
and BCR were compared (167-169). In the series by 
Dogansen and cols. (169), the overall remission rate 
was 46% (65% in cases of MIC and 36% in subjects with 
MAC). A higher remission rate was experienced by 
patients treated with CAB vs. BCR, for both MIC (86% 
vs. 56%) and MAC (45% vs. 27%), respectively (169). 
Menopause might be considered a factor that 
influences the reduction of PRL levels (175). 
Nevertheless, Colao and cols. (163) showed that the 
rate of recurrence of hyperprolactinemia was similar 
among premenopausal and postmenopausal patients. 
There are few studies showing that some patients may 
spontaneously normalize serum PRL concentrations 
after pregnancy. Auriemma and cols. (176) reported that 
pregnancy was associated with normalization of PRL 
levels in 68% of patients. Moreover, breastfeeding did 
not increase the recurrence rate of hyperprolactinemia 
(177). Thus, DA withdrawal has been suggested after 
pregnancy to assess the possibility of hyperprolactinemia 
remission (176,177). Previous pituitary surgery and 
radiotherapy also favor persistent normal PRL levels 
after DA withdrawal (4,6,88).
How long should patients be followedup after 
withdrawal?
The follow-up after DA withdrawal has varied in different 
studies. Generally, the patients have been observed for 
1 to 5 years after cessation of treatment (171,172). 
Most patients relapse within the first year, during which 
the patient should be subjected to a stricter monitoring 
of PRL levels (e.g., every 3 months) (164-169). In 
virtually all studies, all recurrences were observed 
within 24 months of DA discontinuation (162-173). 
In cases of hyperprolactinemia recurrence, the risk of 
tumor growth is very low (< 10%) (88,160,162,169).
COMMENT 10: Following two years of treatment, 
cabergoline (CAB) withdrawal should be strongly 
considered in all patients with microprolactinomas 
and those with macroprolactinomas without visible 
tumor or harboring small tumor remnants, in the 
presence of PRL levels < 10 ng/mL and the use of 
the lowest dose of CAB. Before drug withdrawal, it is 
recommended to gradually taper the CAB dose.
2.6 What is the role of surgery for prolactinomas?
Transsphenoidal surgery (TSS) represents the 
golden standard of surgical approach for both 
microprolactinomas and most macroprolactinomas 
(88), whereas craniotomy must be reserved for tumors 
inaccessible via the transsphenoidal approach and 
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Additional indications for TSS surgery are 
complications of the prolactinomas, particularly the 
management of symptomatic apoplexy (178) and the 
surgical repair of CSF leaks (179). The latter can occur 
spontaneously due to tumor invasion of the sphenoid 
sinus or result from a rapid tumor shrinkage induced by 
DA therapy (180-182). In a recent review, more than 
90% of cases of cerebrospinal fluid leakage were related to 
the use of DA, with a mean time of 3.3 months between 
the start of drug administration and the diagnosis of 
rhinorrhea (182). However, this complication can also 
occur during long-term treatment (183). An additional 
strategy to CSF leakage would be the withdrawal of 
DA to allow tumor re-growth to stop the leak (181). 
As β2-transferrin is only found in CSF, its detection in 
nasal secretions is a very accurate tool for confirming 
the diagnosis of CSF rhinorrhea (179,184).
Table 5. Indications for surgery in prolactinomas 
Increasing tumor size despite optimal medical therapy
Pituitary apoplexy
Intolerance to dopamine agonists 
Resistance to dopamine-agonists
Persistent optic chiasm compression
Cerebrospinal fluid leak during administration of dopamine agonists
Adapted from Refs. 6, 10, and 19.
Efficacy
The most important determinants of successful 
surgery for prolactinoma treatment are the 
experience of the neurosurgeon, moderately 
increased serum PRL levels (< 200 ng/mL), and 
tumor size and invasiveness (6,121). In a literature 
review involving more than 50 series, initial surgical 
remission, defined as the normalization of PRL 
levels, occurred on average in 74.7% and 34% of 
patients with microprolactinomas (MICs) and 
macroprolactinomas (MACs), with a recurrence rate 
of 18% and 23%, respectively (88). More recently, 
the analysis of surgical results from 13 published 
series, including at least 100 patients, has shown the 
control of PRL levels to be achieved in approximately 
73% of 1211 microprolactinomas and 38% of 1480 
macroprolactinomas (185).
Notably, as shown in two recent studies (102,104), 
many patients with partial resistance to CAB achieve 
PRL normalization after surgical debulking, using a 
lower dose of CAB than the presurgical one.
Safety
Complications from TSS for MIC are infrequent, 
the mortality rate being at most 0.6% and the major 
morbidity rate being approximately 3.4% (88,121). 
In patients with large tumors, particularly those 
with giant prolactinomas, the mortality rate ranges 
from 3.3% to 31.2% (88,121). Visual loss, stroke/
vascular injury, meningitis/abscess, oculomotor 
palsy and cerebrospinal fluid rhinorrhea have been 
reported to occur in 0.1%, 0.2%, 0.1%, 0.1% and 
1.9% of cases, respectively (121,186-188). Transient 
diabetes insipidus (DI) is quite common with TSS for 
both micro- and macroadenomas (121). In contrast, 
permanent DI is rare and has been reported to occur in 
approximately 1% of surgeries on MACs (121,187,188). 
Hypopituitarism, commonly found in patients with 
macroadenomas before surgery as a consequence of 
mass effects, has been reported either to further worsen 
or to improve after surgery (102-104).
COMMENT 11: Surgery, usually by the 
transsphenoidal approach, is indicated for patients 
with resistance or intolerance to dopamine agonists; 
macroprolactinomas with chiasmal compression 
and visual impairment without fast improvement by 
medical treatment; and acute tumor complications, 
such as symptomatic apoplexy or cerebrospinal fluid 
leakage.
2.7 What is the role of radiotherapy for 
prolactinomas?
As prolactinomas are among the most radioresistant 
pituitary tumors, PRL normalization occurs in only 
approximately one-third of patients submitted to 
radiotherapy (RT) (88,189,190). Moreover, it is 
associated with a high risk of radiation-induced 
hypopituitarism at 10-20 years (121,191). Therefore, 
RT is only indicated to control tumor growth in DA-
resistant cases not controlled by surgery, as well as in 
the very rare cases of malignant prolactinomas (4,6,88). 
Historically, patients have been treated with both 
external beam radiotherapy and stereotactic techniques 
(189). External beam radiotherapy, also referred to as 
“conventional radiotherapy” (CRT), involves the use of 
multiple non-overlapping beams of X-rays that intersect 
over the target area (191). Stereotactic RT is a form 
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doses of radiation in a single fraction (radiosurgery) or 
in multiple fractions (191). 
Efficacy
A comprehensive review of the literature regarding 
hormonal normalization in patients with prolactinomas 
treated with CRT or radiosurgery concluded that the 
overall normalization rate of both approaches seems to 
be similar (34.1% for CRT vs. 31.4% for radiosurgery) 
(88). In the series by Wan and cols. (190), of the 176 
patients with prolactinomas submitted to gamma-knife 
radiosurgery, 23.3% achieved PRL normalization, 
whereas in 90.3%, the tumor volume decreased or 
remained unchanged. 
Stereotactic techniques deliver less radiation to 
normal brain and nerve tissue in the tumor vicinity. 
Thus, radiation-induced complications are thought 
to be less frequent with radiosurgery than with CRT 
(88,189,190). Moreover, a shorter time to hormonal 
normalization with radiosurgery has been reported in 
some series (189,191), but not in all (192).
Currently, radiosurgery has been the recommended 
treatment option unless the tumor is larger than 3-4 
cm, or within 3 mm of the optic nerves, chiasm or tracts 
(192). In this situation, patients should be offered 
CRT or, whenever possible, stereotactic RT in multiple 
fractions (88,189-191).
Safety
The use of convention radiotherapy (CRT) is associated 
with the development of several severe complications 
(121). More than 50% of patients receiving pituitary 
radiotherapy will develop at least one anterior 
pituitary hormone deficiency within the following 
decade (193,194). Although hypopituitarism tends 
to arise in the first 5 years after radiation treatment, 
new deficiencies can appear even 20 years later 
(103,176,177). Additional complications of CRT 
include cerebrovascular accidents (CVAs), a second 
brain tumor and optic nerve injury. The incidence 
of CVA has been found to increase from the time of 
radiation, from 4% at 5 years to 11% at 10 years and 
21% at 20 years (121,195). The cumulative risk of 
second brain tumors has been demonstrated to range 
from 2.0% at 10 yr, to 2.4% at 20 yr, and 8.5% at 30 
yr (196). The rate of presumed radiation-induced 
optic neuropathy has been estimated to be 0.8% at 10 
years (197). Another rare complication is radiation-
induced necrosis of the surrounding brain tissue, with a 
prevalence of approximately 0.2-0.8% (88,121).
In patients receiving radiosurgery, hypopituitarism 
has been found to be the most common complication, 
occurring in approximately one-third of patients 
(121,198). Clinical deterioration due to visual field loss 
and worsened facial sensory loss, as well as a handful 
of cases of second brain malignancies have also been 
reported (88,191,199). 
These data suggest the greater safety of radiosurgery 
compared to CRT. However, further studies of large 
series and with long follow-ups are required to draw 
definitive conclusions (121). 
COMMENT 12: Due to its low efficacy and 
potentially severe side-effects, radiation therapy is 
only indicated to control tumor growth in DA-
resistant cases not controlled by surgery. Whenever 
possible, preference should be given to stereotactic 
techniques.
2.8 How giant prolactinomas should be managed? 
Although there is no consensus on the definition of 
giant prolactinomas (GPs), they are usually defined as 
tumors with a maximum diameter greater than or equal 
to 4 cm (200-202).
GPs represent only 2-3% of all prolactinomas, and 
they are more commonly found in middle-aged men 
(200,201). These tumors are usually more aggressive in 
men than in women (203). GPs often cause visual field 
defects and/or ophthalmoplegia due to compression of 
the optic chiasm and/or cranial nerves, respectively, and 
headaches, as well as other neurological alterations and 
other atypical manifestations for a pituitary adenoma, 
such as orbital invasion, epistaxis or obstructive 
hydrocephalus (204-207). Panhypopituitarism may 
also be present. Therefore, formal visual testing is 
usually necessary, and pituitary function evaluation is 
mandatory (200,203).
Different therapeutic approaches, such as dopamine 
agonists (DAs) alone or in combination with surgery 
and radiotherapy, may be necessary to reach the 
therapeutic goals in patients with GPs, which include 
tumor volume control, normalization of the PRL level 
and restoration of eugonadism (200). Temozolomide 
(TMZ) has been used in aggressive prolactinomas that 
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(117-119). Due to the large tumor volume and 
commonly invasive behavior, control of mass effects 
should be a priority in the management of patients with 
giant prolactinomas (88).
Dopamine agonists
As medical therapy in most cases causes a marked and 
rapid reduction of the tumor size, it is considered the 
first-line treatment option in patients with GPs, even 
in the presence of visual abnormalities. However, close 
monitoring of the visual field is mandatory (200-202). 
In this setting, early surgery (e.g., within 15 to 30 days) 
may occasionally be necessary if the tumors do not 
shrink and if severe visual field defects do not improve 
or even get worse (200-202). 
The use of DA for GPs seems to reduce significantly 
the tumor mass (> 30% decrease in tumor diameter or 
> 65% reduction in tumor volume) in 74% of the cases 
and to normalize the PRL level in 60% of the cases 
(200). Cabergoline (CAB) is the preferred DA for the 
medical management of GPs due to its greater efficacy 
and better tolerability compared to BCR (34,88). In 
the series by Espinosa and cols. (208), CAB treatment 
resulted in the normalization of PRL levels in 68% and 
in the reduction of > 50% in tumor volume in 87% of the 
GP patients. The composite goal of PRL normalization 
and > 50% tumor reduction was achieved by 55% of 
patients with GPs (n = 26) and by 66% of patients with 
no giant macroprolactinomas (n = 100) (p = 0.19) 
(208). Among GPs ≥ 6 cm, DA treatment achieved 
PRL normalization in 11/18 (61%) patients within 
a median interval of 20 months (209). In the series 
by Vilar and cols. (210), 10 of 16 patients (62.5%) 
reached PRL normalization at weekly doses ranging 
from 2.5 to 7 mg. Regarding DA withdrawal, there 
are no data in the literature about CAB withdrawal 
in patients with GPs. Concerning BRC withdrawn in 
these patients, some authors described the persistence 
of normoprolactinemia and tumor volume shrinkage in 
only a minority of patients (211-213).
Surgery
Neurosurgery should be considered as part of the 
multidisciplinary approach to patients with DA-
resistant prolactinoma (debulking surgery) or should 
be restricted to some acute complications such as 
apoplexy or leakage of cerebrospinal fluid during DA 
therapy (4,206,214). Neurosurgery could also be 
considered for patients with severe visual field defects 
that do not show any improvement or even worsen 
during DA treatment. The transsphenoidal approach is 
usually the first choice, even for GPs (200). In patients 
with giant and invasive prolactinomas, surgery is hardly 
curative, regardless of the surgical technique employed 
or the neurosurgeon’s experience. Therefore, in these 
cases, the goal of surgery is to debulk the tumor in 
order to improve the symptoms related to mass effects 
(88,121). Debulking surgery may also improve the 
tumor response to DA therapy (102,104).
Radiotherapy 
Radiotherapy should be used in patients with GPs who 
do not achieve disease control with DA therapy and 
surgery, particularly regarding mass effects (200-202).
Temozolomide
Temozolomide is an oral alkylating chemotherapeutic 
agent that exerts cytotoxic effects through methylation 
of DNA and can be used in aggressive giant 
prolactinomas that remain uncontrolled in terms of 
mass effects despite the multiple treatment modalities 
previously mentioned. The standard dose is 150–200 
mg/m2 for 5 days, repeated every 28-days in a cycle 
(117,119).
COMMENT 13: Cabergoline is the therapy of 
choice for patients with giant prolactinomas (GPs), 
as this drug enables normalization of prolactin levels 
and significant tumor reduction in the majority of 
cases, but higher doses are often required, compared 
to those for smaller macroprolactinomas. Surgery 
should be considered as part of the management 
of these patients, especially in patients who still 
have a large tumor load despite dopamine agonist 
therapy. Radiotherapy and/or temozolomide should 
be reserved for the subgroup of GPs that are not 
controlled in terms of mass effects regardless of the 
multiple conventional treatment modalities.
2.9 How to manage the challenges involving 
prolactinomas and pregnancy?
Chronic anovulation and infertility are very frequent 
among women with prolactinomas, mostly due to 
the hypogonadotropic hypogonadism related to 
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decreases the luteinizing hormone (LH) pulse amplitude 
and frequency through the suppression of GnRH (14). 
This effect appears to be mediated by an earlier step 
of suppressing the generation of kisspeptin, a protein 
made by neurons in the arcuate and periventricular 
nuclei of the hypothalamus, which stimulates GnRH 
release (215). PRL can also decrease estrogen and 
progesterone production through direct effects on the 
ovaries (216). Fertility is, however, restored in most 
women with the use of DA. In the absence of hormonal 
control in cases with microprolactinomas, clomiphene 
citrate or recombinant gonadotropins may be used for 
ovulation induction (216,217).
During pregnancy, the primary concern is growth of 
the tumor because of high levels of estrogens, leading 
to visual disturbances and headache. The second 
point of concern is the fetal expo sure to DA in early 
embryogenesis and the poten tial risk of malformations 
(216,217). 
Tumor growth 
Prolactinomas can enlarge during pregnancy as a result 
of both the stimulatory effect of these high estrogen 
levels and the discontinuation of the dopamine agonist 
that might have caused tumor shrinkage (216). In 
microprolactinomas, the chance of clinically significant 
tumor growth is less than 5%; therefore, after pregnancy 
confirmation, DA can be withdrawn, and the patient 
should be monitored clinically every trimester. In 
contrast, in patients with macroadenomas, the risk of 
tumor growth with clinical repercussion is up to 35% 
(217). However, Holmgren and cols. (218) noted 
a reduced risk of tumor growth during preg nancy 
in patients treated with BRC for at least 12 months. 
Thus, in patients with expansive macroprolactinomas, 
it is mandatory to observe a tumor within the sellar 
boundaries and usually to wait at least 1 year under 
treatment with a DA (217,219). 
DAs safety in the fetus 
BRC has been shown to cross the placenta in human 
studies (103); CAB has been shown to do so in 
animal models, but such data are lacking in humans 
(121,216). As a general approach in pregnancy, DAsare 
discontinued as soon as pregnancy is con firmed (216). 
Nevertheless, taking into account that CAB has a long 
half-life and can be detected in the circulation within 
30 days after drug with drawal, early fetal exposure is 
unavoidable (217). Moreover, the experience with this 
drug is still limited compared to BRC: ~950 vs. ~6200 
pregnancies induced by CAB and BRC, respectively 
(216). These facts are the rational for BRC preference 
in hyperprolactinemic women willing to become 
pregnant (217), as recommended by the Guidelines 
of the Endocrine Society, with BRC being the only 
authorized DA for pregnancy induction (4). However, 
in clinical practice, CAB has often been used for this 
purpose with no apparent damage to the fetus (216). 
The potential fetal malformation and im pairment of the 
dopaminergic brain circuitry under DA use are a concern 
(216,217,219). Addressing this issue, Molitch (216) 
has compared outcomes data from 6239 pregnancies 
induced by BCR with 968 pregnancies induced by CAB 
and pregnancies in the US general population, regarding 
miscarriages, births at term, premature births, multiple 
pregnancies, and malformed newborns. Overall, no 
difference was found among the three groups (216).
In the vast majority of cases, the DA was with-
drawn at up to 6 weeks of pregnancy. In the literature, 
there are only data on approximately 100 cases of 
BRC use throughout pregnancy, which have disclosed 
one case of undescended testis and one case of talipes 
deformity (217,220,221). Recently, a compilation of 
15 pregnancies with the use of CAB during the entire 
pregnancy has shown 12 healthy babies and one fetal 
death by severe pre-eclampsia (222).
Concerning the long follow-up of children 
conceived during BRC treatment, Bronstein followed 
up 70 children, during 12 to 240 months, and there 
was one case of idio pathic hydrocephalus, one child 
with tuberous sclerosis and another one with precocious 
pu berty (223). In two other studies (217,224), no 
impairment of physical development was observed.
In four studies, the follow-ups of children con-
ceived on CAB were described. Bronstein (223) and 
Ono and cols. (225) did not find any abnormalities in 
five and 83 children followed for 41 months and 12 
years, respectively. Leb be and cols. (226) following 88 
children described two cases of slight delay in verbal 
fluency and one case of difficulty in achieving complete 
conti nence. Moreover, Stalldecker and cols. (227) 
followed 61 children and found two cases of seizures 
and two cases of pervasive developmental dis order.
In summary, BCR and CAB seem to be equally 
safe for the fetus; none of these drugs are apparently 
associated with increased risk for abortions or 
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in infertile hyperprolactinemic women. Ideally, CAB 
should be discontinued 30 days before the conception 
(216,218,223).
The best approach
An algorithm proposed by Glezer and cols. (217) for the 
management of prolactinoma during preg nancy is shown 
is Figure 8. The DA should be withdrawn as soon as 
pregnancy is confirmed in patients with microadenomas 
or enclosed macroadenomas. Assessment of tumor 
shrink age in macroadenomas is mandatory before 
pregnancy allowance. In previously expanded or invasive 
tumors, the choice of BRC main tenance throughout 
pregnancy or its reintro duction if needed, or else the 
indication of previous surgical debulking, depends on 
the physician’s and patient’s decision (217).
Patients with microprolactinomas (MICs) or 
enclosed macroprolactinomas (MACs) should be 
followed each trimester, with attention to headache 
and visual impair ment (217). In the pres ence of those 
complaints, sellar MRI without contrast, preferably 
after the first trimester, should be performed, and 
BRC reintroduc tion is indicated if tumor growth is 
related to the clinical findings (217). In cases of BCR 
intolerance, CAB, although off-label, could be used 
instead (217,219,222). On the other hand, in pa tients 
with expanding MACs, DA maintenance throughout 
pregnancy should be evaluated by an expert (217,219). 
Clinical evalua tion monthly and neuroophthalmological 
evalu ation each trimester are indicated. In patients 
with MICs or MACs experiencing symptoms related 
to mass effects and without improvement with clinical 
treatment, neuro surgery should be performed, 
preferably during the second trimester (216,217). An 
alternative approach might be delivery of the baby, 
if the pregnancy is sufficiently advanced (e.g., > 37 
weeks) (216,217,219).
Notably, during pregnancy, periodic checking 
of PRL levels is of no diagnostic benefit and can be 
misleading (216,217). Indeed, in normal women, PRL 
levels rise with gestation, but PRL levels do not always 
rise with tumor enlargement, and tumor enlargement 
can occur without a change in the PRL concentration 
(216). A rise in PRL may well not indicate tumor 
enlargement and therefore may cause unnecessary 
worry. By contrast, the lack of a rise in PRL may be 
falsely reassuring in a patient with headaches or other 
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Figure 8. Algorithm suggested for the prolactinoma management during 
pregnancy (PRL: prolactin; BCR: bromocriptine; MRI: magnetic resonance 
imaging) (Adapted from Ref. 217).
Follow-up
After pregnancy, PRL levels and tumor size should be 
reassessed because reduction, or even complete tumor 
disappearance, after pregnancy may occur. Moreover, 
asymptomatic tumor enlargement may occur during 
pregnancy (216,217). It has been suggested that high 
levels of estrogen during pregnancy can induce areas 
of tumor necrosis and apoptosis. The median rate of 
hyperprolactinemia remission after preg nancy in eight 
studies was 27%, ranging from 10 to 68% (217).
Breastfeeding does not seem to be associated with 
tumor growth risk, and it is allowed in patients who did 
not require DA during pregnancy (216-219).
COMMENT 14: In the large majority of cases, 
a dopamine agonist is only necessary to induce 
pregnancy and should be discontinued as soon as 
pregnancy is confirmed. Nevertheless, in selected 
cases harboring invasive macroprolactinomas or 
in patients with marked growth and visual and/
or headache complaints, the drug may be used 
throughout pregnancy.
COMMENT 15: Bromocriptine and cabergoline 
seem to be equally safe for the fetus, when used for 
pregnancy induction. Indeed, short-term exposure 
to these drugs for less than 6 weeks of gestation has 
not been found to cause any increase in spontaneous 
abortions, ectopic pregnancies, trophoblastic disease, 
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2.10 How to manage the psychotropic-induced 
hyperprolactinemia?
It should always be kept in mind that patients with 
apparent psychotropic-induced hyperprolactinemia 
may have an alternative etiology for the PRL elevation, 
such prolactinomas, primary hypothyroidism, 
macroprolactinemia, or pseudo-prolactinoma (1). 
Ideally, a baseline PRL level should be obtained before 
starting psychotropic medications known to increase 
PRL, but in the majority of cases, this is not practically 
possible, particularly when these medications are started 
urgently (4,44). Endocrine Society Guidelines suggest 
discontinuing the drug for 3 days or substituting 
with an alternative drug if psychotropic-induced 
hyperprolactinemia is suspected and then remeasuring 
PRL (4). Nevertheless, the decision to withdraw or 
substitute the medication should always be made in 
consultation with the patient’s psychiatrist (4,46). If 
the drug cannot be safely withdrawn due to the risk 
of a relapse of psychiatric symptoms and if the onset of 
hyperprolactinemia does not coincide with the initiation 
of therapy, then pituitary MRI should be performed to 
exclude or diagnose a sellar region lesion (4,46).
The different approaches proposed for symptomatic 
patients with confirmed psychotropic-induced 
hyperprolactinemia include (i) switching the offending 
drug to aripiprazole or other atypical antipsychotics 
(AAPs) with a low effect on PRL levels (41,209-211) 
and (ii) adding DA therapy (41).
Switching to aripiprazole or other AAPs
Because the atypical antipsychotic aripiprazole is a partial 
D2 receptor agonist, it has a neutral effect on PRL 
levels and may often decrease them (46, 228). Thus, 
it may be used as alternative therapy for patients with 
antipsychotic-induced hyperprolactinemia (46,228). 
Other atypical antipsychotics, such as quetiapine, 
olanzapine, lurasidone, asenapine, or clozapine, cause 
only a mild elevation in PRL levels, and only in a 
subgroup of those treated (43,46). Therefore, these 
drugs may also serve as alternatives to antipsychotics 
with robust effects on PRL (e.g., risperidone) (43,46). 
However, in patients who are clinically very stable 
on antipsychotic treatment, switching to a different 
antipsychotic such as aripiprazole or other atypical 
antipsychotics may be inappropriate (46-48). In these 
cases, using aripiprazole as adjunctive therapy may be 
useful. Indeed, in a placebo-controlled trial, adjunctive 
aripiprazole normalized drug-induced hyperprolactinemia 
in more than 80% of patients with schizophrenia (229). 
More recently, in a double-blind, randomized, placebo-
controlled trial involving patients with risperidone-
induced hyperprolactinemia, normalization of PRL 
levels was encountered in 46% of patients who received 
adjunctive aripiprazole therapy (49).
Very interestingly, aripiprazole therapy was 
recently shown to be effective in normalizing PRL 
levels and in reducing tumor size in two patients with 
microprolactinomas and psychotic symptoms (230,231). 
Adding DA therapy 
The use of DA in the treatment of antipsychotic-
induced hyperprolactinemia is not well studied (46,47). 
DA and antipsychotic medications may have opposing 
mechanisms of action. Indeed, the therapeutic effects of 
most antipsychotics come from D2 receptor antagonism 
(232,233). Thus, there is a concern that DA therapy 
may reduce the effectiveness of antipsychotic drugs and 
trigger relapse or exacerbation of psychosis (46). There 
is, however, little evidence to support this concern. For 
instance, Chang and cols. (234) reported a cabergoline-
induced psychotic exacerbation in three schizophrenic 
patients when CAB was introduced for the treatment 
of the hyperprolactinemic symptoms. Likewise, Santos 
Andrade and cols. (235) described a similar situation 
when BCR was added for macroprolactinoma treatment 
in a patient with schizophrenia on haloperidol. By 
contrast, in 5 studies that involved 174 schizophrenic and 
bipolar patients and had a duration ranging from 8 weeks 
to 6 months, the association of dopamine antagonists 
with low doses of CAB or BCR for the treatment of 
hyperprolactinemic symptoms apparently did not impair 
the underlying psychiatric disorder (236-240).
DA therapy should therefore be reserved for patients 
with severe hyperprolactinemia who fail to respond to 
aripiprazole as an alternative or adjunctive treatment. Due 
to its higher specificity for the D2 receptor, CAB would be 
preferable to BCR in the management of antipsychotic-
induced hyperprolactinemia. Nevertheless, it should be 
used cautiously, in doses as low as possible (46).
COMMENT 16: The best approach for symptomatic 
antipsychotic-induced hyperprolactinemia would be 
the use of aripiprazole as an alternative or adjunctive 
therapy. DA therapy at low doses can be used cautiously 
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